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Available online 7 June 2016Parkinson's disease (PD) is a neurodegenerative disease where the degeneration of the nigrostriatal pathway
leads to speciﬁc motor deﬁcits. There is an unmet medical need for regenerative treatments that stop or reverse
disease progression. Several growth factors have been investigated in clinical trials to restore the dopaminergic
nigrostriatal pathway damaged in PD. Platelet-derived growth factor-BB (PDGF-BB), a molecule that recruits
pericytes to stabilize microvessels, was recently investigated in a phase-1 clinical trial, showing a dose-depen-
dent increase in dopamine transporter binding in the putamen of PD patients. Interestingly, evidence is accumu-
lating that PD is paralleled bymicrovascular changes, however, whether PDGF-BBmodiﬁes pericytes in PD is not
known.
Using a pericyte reportermouse strain,we investigate the functional and restorative effect of PDGF-BB in a partial
6-hydroxydopaminemedial forebrain bundle lesionmousemodel of PD, andwhether this restorative effect is ac-
companied by changes in pericyte features.
We demonstrate that a 2-week treatmentwith PDGF-BB leads to behavioural recovery using several behavioural
tests, and partially restores the nigrostriatal pathway. Interestingly, we ﬁnd that pericytes are activated in the
striatum of PD lesioned mice and that these changes are reversed by PDGF-BB treatment.
The modulation of brain pericytes may contribute to the PDGF-BB-induced neurorestorative effects, PDGF-BB
allowing for vascular stabilization in PD. Pericytes might be a new cell target of interest for future regenerative
therapies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Neurorestoration1. Introduction
Parkinson's disease (PD) is the secondmost commonneurodegener-
ative disorder, with a progressive loss of the dopaminergic (DA) neu-
rons in the substantia nigra pars compacta (SNpc) and an associated
loss of DA striatal ﬁbres (de Rijk et al., 1997). The lack of dopamine in
the striatum is associated with typical motor symptoms such as brady-
kinesia, rigidity, tremor and balance problems (Fearnley and Lees,
1991).
There is an unmet clinical need for effective and long-lasting
neurorestorative strategies to prevent further degeneration of
nigrostriatal neurons and axons, and to slow disease progression.aniaUniversity Hospital, 22185
.
ect.com).
. This is an open access article underEvidence is accumulating that vascular alterations, in particular an-
giogenesis, may be a possible mechanism involved in the pathogenesis
of PD (Faucheux et al., 1999; Janelidze et al., 2015; Wada et al., 2006;
Yasuda et al., 2007). Pericytes are one of the key players in angiogenesis
and blood-brain-barrier integrity (Armulik et al., 2010). They also con-
tribute to local homeostasis, secrete growth factors (Shimizu et al.,
2012) and inﬂammatory molecules (Kovac et al., 2011) and are
multipotent cells (Dore-Duffy, 2008; Ozen et al., 2012; Ozen et al.,
2014; Paul et al., 2012). Importantly, cerebral pericytes express plate-
let-derived growth factor (PDGF) receptor β (PDGFRβ) (Winkler et al.,
2010), and are recruited by PDGF-BB-secreting endothelial cells to sta-
bilize newly formed blood vessels (Armulik et al., 2005). PDGF-BB is
an endogenous growth factor that not only plays a role in angiogenesis,
but also has neuroprotective effects on DA neurons in vitro (Nikkhah et
al., 1993; Pietz et al., 1996), and has been shown to restore the
nigrostriatal pathway in different partial lesion PD models in vivo
(Zachrisson et al., 2011). Based on these ﬁndings, PDGF-BB has enteredthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Design of the experiment. Animals were lesioned in the MFB with 6-OHDA or saline
(controls) and allowed to recover for the next 3 weeks. Mice then underwent a battery of
behavioural tests to select partially lesioned mice, before receiving either PDGF-BB or
vehicle treatment into the lateral ventricle for 2 weeks. Once the mini-pump was
removed, animals were either sacriﬁced immediately after treatment, or kept for 6 more
weeks, where behavioural tests were performed 6 to 8 weeks after the treatment,
before mice were sacriﬁced. MFB: medial forebrain bundle; i.c.v.: intracerebroventricular.
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evaluated in PD patients (Paul et al., 2015). However, it is currently un-
clear whether PDGF-BB can induce long-lasting improvement of symp-
toms and whether it alters features of pericytes.
Neuroprotective and neurorestorative interventions in PD require
models that resemble earlier stages of PD, where some DA cells and ﬁ-
bres still remain. We therefore use a partial lesion PD model in
pericyte-reporter mice (Boix et al., 2015). This model allows for a quan-
tiﬁable behavioural and histological readout in order to study the effect
of intracerebroventricular (i.c.v.) administration of PDGF-BB on motor
symptoms. 6-hydroxydopamine (6-OHDA)was injected into themedial
forebrain bundle (MFB) to avoid injection of the toxin in target regions
for neuroprotection and vascular changes, such as the striatum.
We examine if behavioural recovery is associated with nigrostriatal
DA pathway restoration in this model immediately and 2 months after
treatment. Further, we speciﬁcally examine whether a partial 6-OHDA
lesion is accompanied by pericyte alterations andwhether these chang-
es are affected by PDGF-BB.
2. Material and methods
2.1. Animals
We used 45male rgs5GFP/+ knock-out/knock-in mice (C57bl/6 back-
ground) (Nisancioglu et al., 2008). In this reporter mouse, the Green
ﬂuorescent protein (GFP) gene is expressed in the cytoplasm under the
pericyte-speciﬁc Regulator of G protein signalling 5 (RGS5) promoter,
making it possible to track pericytes. Mice have a normal phenotype.
Animals were housed in a 12 h/12 h light/dark cycle with access to
food and water ad libitum. All experiments were carried out in accor-
dance with the European Directive 2010/63/EU guidelines, and ap-
proved by the Ethical Committee at Lund University.
2.2. Partial 6-hydroxydopamine lesion model
A partialMFB 6-OHDA lesionwas performed as described previously
(Boix et al., 2015). At the day of surgery, animals weighed 25–30 g. An-
imals were anesthetized with 5% isoﬂuorane (IsoFlo vet,
Apoteksbolaget, Sweden), diluted in a 2:1 oxygen:nitrous oxidemixture
for 2 min and placed on the stereotaxic frame. Mice received 2%
isoﬂuorane throughout the entire surgery (ca. 30 min). 100 μL Marcain
(0,25 mg/mL, Apoteksbolaget, Sweden) was injected subcutaneously
(s.c.) on top of the skull as a local analgesia, and a skin cut b1 cm was
performed to expose the skull. 6-OHDA (Sigma) was dissolved in 0.9%
NaCl and 0.02% ascorbic acid to reach a ﬁnal concentration of 1 μg/μL,
and the solution was used within the next 3 h. 6-OHDA was injected
into the right MFB at the following coordinates from the bregma:
antero-posterior (A/P) = −1.2; medio-lateral (M/L) = −1.3; and
dorso-ventral (D/V) = −4.75 (according to the dura mater), using a
10 μL-Hamilton syringe connected to a glass capillary (tip diameter ca.
50 μm), with a ﬂow rate of 0.5 μL/min (ﬁnal volume = 1 μL). Sham-le-
sioned animals received only 1 μL of 0.9% NaCl with 0.02% ascorbic
acid. Sham-lesioned animals are referred to as controls hereafter. The
glass capillary was left in place for the following 5 min to avoid back-
ﬂow, before being slowly retracted. The skin was sutured, animals re-
ceived 0.9% NaCl s.c. (1 mL) and daily care the ﬁrst week with food
soaked in 10% sucrose and high calorie jelly food (DietGel Boost, Clear
H20 Co.). Animalweight losswasmonitored not to be N15% of the initial
weight.
2.3. Behavioural tests
Three weeks after the 6-OHDA lesion, animals underwent a battery
of behavioural tests to assess the degree of the unilateral nigrostriatal le-
sion. Mice with a partial lesion (n=38 out of n=45) were selected as
previously described (Boix et al., 2015). Brieﬂy, we have previouslyshown that certain behavioural tests can reliably predict the degree of
cell loss in MFB lesioned mice, whereby the stepping test and the am-
phetamine-induced rotation test are the best predictors (for details
see Boix et al., 2015). Four animals had a total lesion, one only a mild le-
sion and two animals died before the end of the experiment.
For all tests, animals were habituated to the room at least 2 h before
the test. The same behavioural tests were then performed 13–15weeks
after the 6-OHDA lesion (Fig. 1).
2.3.1. Corridor test
For body lateralization assessment, animals performed the corridor
test, adapted for mice (Grealish et al., 2010). Brieﬂy, animals were
food-restricted and kept at 85% of their initial bodyweight for the entire
test time (7 days). They were ﬁrst habituated to the corridor (60 cm-
long, 4 cm-wide and 15 cm-high)with sugar pellets randomly scattered
on the ﬂoor, 10min per day, for the ﬁrst 2 days. From day 3 to day 7, an-
imals were habituated to an empty corridor for 5 min, and then placed
in a corridor presenting 10 pots on each side, spaced by 5 cm and con-
taining 2 to 3 sugar pellets in each. Contralateral and ipsilateral re-
trievals were scored until either 20 retrievals were counted or 5 min
elapsed.
2.3.2. Stepping test
To assess forelimb akinesia, the stepping test was used as previously
described for mice (Blume et al., 2009). Mice were lifted gently from
their tail and pulled backward in a 50 cm-long, 10 cm-wide corridor,
within 10 s. The test was repeated 3 to 5 times per animal, and the
whole experiment was videotaped and analysed using a slow motion
video player (VLC software). Contralateral and ipsilateral forelimb
adjusting steps were quantiﬁed.
2.3.3. Cylinder test
Mice performed the cylinder test to evaluate spontaneous forelimb
lateralization (Schallert et al., 2000). Animals were placed in a glass cyl-
inder (19 cm-diameter, 20 cm-high) with mirrors behind to allow a
360° vision. Mice were left to explore for 3 min, and the whole experi-
ment was videotaped and analysed using a slow motion video player
(VLC software). Contralateral and ipsilateral wall touches (contact
with full digits) were quantiﬁed.
2.3.4. Drug-induced rotation tests
To assess rotational asymmetry, animals were tested with apomor-
phine and amphetamine (Ungerstedt and Arbuthnott, 1970). Mice
were placed in an automated rotometer apparatus (Omnitech electron-
ics) consisting of a glass bowl (50 cm-diameter) covered with bedding,
where mice were harnessed and left to habituate for 15 min. For apo-
morphine-induced rotation test, animals were primed 4 and 2 days be-
fore the test with a s.c. injection of apomorphine (Sigma) at a
concentration of 0.1 mg/kg, dissolved in 0.9% NaCl and 0.02% ascorbic
acid. They received the same dose on the test day. Contralateral and ip-
silateral turns were recorded for 40min, and the net contralateral turns
were calculated. At least 3 days after, animals were placed in the
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5 mg/kg D-amphetamine (Sigma) dissolved in 0.9% NaCl and 0.02%
ascorbic acid (injected volume= 200 μL). The contralateral and ipsi-
lateral turns were recorded for 40 min, and the net ipsilateral turns
were evaluated.
2.4. PDGF-BB mini-osmotic pump implantation
5 weeks post lesion (Fig. 1), a mini-osmotic pump (Alzet, model
1004) was implanted. For this, animal anaesthesia and local analgesia,
placement on the stereotaxic frame, and skin cut were performed sim-
ilarly as described above (see Partial 6-hydroxydopamine lesion model).
The catheter was implanted into the right lateral ventricle (A/
P=−0.5; M/L =−1 and D/V =−2 according to the dura mater), at-
tachedwith glue (loctite 454 glue; Alzet) and linked to themini-osmot-
ic pump by a ca. 3 cm-long plastic tube (brain infusion kit; Alzet). The
mini-osmotic pump was inserted s.c. in the back of the animal (pump
ﬂow rate: 0.11 μL/h) and contained human recombinant PDGF-BB
(R&D System) diluted in artiﬁcial cerebrospinal ﬂuid (aCSF; 148 mM
NaCl, 3 mM KCl, 1.4 mM anhydrous CaCl2, 0.8 mM MgCl2, 1.5 mM
Na2HPO4, 0.2 mM NaH2PO4) and supplemented with mouse serum al-
bumin (100 μg/mL; Sigma) and gentamicin (50 μg/mL; Life Technolo-
gies) in order to reach a delivery rate of 36 ng of PDGF-BB per day.
Animals were randomly assigned to either vehicle-infused sham-le-
sioned group (controls, n = 14), vehicle-infused 6-OHDA-lesioned
group (n = 12), or PDGF-BB-infused 6-OHDA-lesioned group (n =
12). Mice were treated for 14 days with PDGF-BB or vehicle solution.
The vehicle solution contained aCSF, mouse serum albumin and genta-
micin at the same concentrations. Themini-osmotic pumpwas then re-
moved after 14 days. A skin cut b1 cm was done on the back of the
animal for the mini-osmotic pump to be gently pulled out, and the
tubewas cut and cloggedwith glue, before suturing the animal. Animals
were randomly selected for short term or long-term survival and brains
processed for histology (n= 26) or protein analysis (n= 12).
2.5. Tissue processing
Animals were sacriﬁced either within 12 h after (referred later as
“shortly after”) or 8 weeks after PDGF-BB or vehicle treatment (Fig. 1).
For immunohistochemistry, animals (vehicle-treated sham group:
n = 10; vehicle-treated lesioned group: n = 8; PDGF-BB-treated le-
sioned group: n = 8) were deeply anesthetized with an i.p. injection
of a lethal dose of sodium pentobarbital (Apoteksbolaget, Sweden),
and were transcardially perfused with ﬁrst 0.9% NaCl for 5 min, and
then by cold 4% paraformaldehyde (PFA) for 5 min. Brains were re-
moved and PFA post-ﬁxed for 24 h, before incubating them in 30% su-
crose for several days. They were placed on a frozen microtome and
coronal sections were cut at 30 μm-thick, in a 1:10 series. Sections
were kept in an anti-freeze solution and stored at 4 °C until further
analysis.
For western blot analysis, mice (all different groups: n = 4) were
sacriﬁced by cervical dislocation, brains were removed and cut on ice
in a 1 mm-thick coronal sections. The striatumwas carefully delineated
using the corpus callosum and the lateral ventricles as reference points,
taken out and frozen in liquid nitrogen. The tissue was kept in−80 °C
freezer.
2.6. Immunohistochemistry
Sections were washed 3 times in phosphate buffer saline (PBS) and,
for brightﬁeld staining, endogenous peroxidase was quenched with 3%
H2O2 and 10%methanol diluted in PBS. For PDGFRβ, a heat-induced epi-
tope retrieval was performed by incubating the sections in citrate buffer
at 80 °C for 30min, before letting them cool down at room temperature
(RT) for 15min. Sectionswere then incubated ﬁrstwith a blocking solu-
tion containing 5% normal goat serum (NGS) diluted in 1% TritonX-100/PBS (PBSTX) for 30min at RT, and then with primary antibodies diluted
with 3% NGS in PBTX, overnight at RT: rabbit anti-Tyrosine hydroxylase
(TH; 1:1000;Millipore), chicken anti-GFP (1:5000; Abcam), rabbit anti-
human PDGFRβ (1:200; Cell Signalling), rat anti-mouse CD13 (1:100;
AbDSerotec), rabbit anti-Chondroitin sulfate proteoglycan NG2 (NG2;
1:200; Millipore) and rabbit anti-Glucose transporter 1 (GLUT1;
1:400; Abcam).
For brightﬁeld staining, sections were washed 3 times 10 min and
incubated with the biotinylated goat anti-rabbit secondary antibody
(1:200; Vector Laboratories), in 3% NGS diluted in PBSTX, for 2 h at RT.
Theywere rinsed 3 times 10min and secondary antibody signalwas en-
hanced with an avidin-biotin solution (Vectastain Elite ABC kit; Vector
Laboratories), 1 h at RT. Sectionswerewashed as above and the antigen
was revealed using the chromogen 3,3-diaminobenzidine (DAB Peroxi-
dase Substrate Kit; Vector Laboratories). Sections were washed,
mounted and left to dry overnight at RT. Theywere dehydrated in grad-
ual ethanol concentrations, incubated 2 × 5 min in Xylene and
coverslipped using DPX mounting medium.
For immunoﬂuorescence, sectionswerewashed 3 times 10min after
the primary antibodies and incubated with the corresponding second-
ary antibodies diluted in 3% normal donkey serum in PBSTX, for 1 h at
RT: CY3-conjugated donkey anti-rat IgG, CY3-conjugated donkey anti-
rabbit IgG, AlexaFluor 647-conjugated donkey anti-rabbit IgG and
CY5-conjugated donkey anti-rat IgG (1:500; Jackson ImmunoResearch).
For GFP staining, sections were incubated with a biotinylated goat anti-
chicken secondary antibody (1:200; Vector Laboratories) for 2 h at RT,
washed 3 times 10min and then incubated with AlexaFluor 488-conju-
gated Streptavidin (1:2000; Life Technologies) for 2 h at 4 °C. Sections
were washed as above and incubated with DAPI (1:1000 diluted in
PBS) for 10min at RT, rinsed 3 times 10min,mounted and coverslipped.
2.7. TH+ nigral cell quantiﬁcation
To estimate the TH+ cell number in the SNpc, unbiased stereology
countingwas performed using the optical fractionator probe (Stereo In-
vestigator software). Sections were placed on a Nikon 80i microscope
presenting X-Y motorized stage and a Z-axis motor (Leica). SNpc area
was delineated at magniﬁcation 5× and TH+ cells were counted at
100 X. TH+ cells were counted only when the cell soma was inside
the stereology box or touching the including line. 4 to 6 SNpc sections
were used per brain, on average, in a 1:5 series, and the sampling inter-
val was adjusted to have a Gundersen coefﬁcient of error b 10% (aver-
age = 7%). TH+ cell estimation was calculated according to the
following formula:
N ¼∑Q  1
asf
 1
hsf
 1
ssf
where∑Q is the total cell count, asf is the area sampling fraction hsf is
the height sampling fraction and ssf is the section sampling fraction
(West, 1999).
2.8. TH+ striatal ﬁbre quantiﬁcation
TH+ striatal ﬁbre density was estimatedwith densitometry. For this,
4 high-resolution pictures of the striatumwere taken per brain, at mag-
niﬁcation 10×, using a brightﬁeld Nikon microscope, spanning from
+1.18 to−0.1 according to bregma. The striatumwas divided into dor-
sal and ventral equal-halves according to the dorso-ventral axis (includ-
ing the nucleus accumbens), delineated and the optical density was
calculated using the ImageJ software (National Health Institute, USA).
The measured values were then corrected for the background staining
by subtracting optical density measure of the corpus callosum, for
each picture.
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For pericyte counts, sectionswere analysedwith a brightﬁeldmicro-
scope for PDGFRβ+ cell counts, and a Zeiss LMS510 confocalmicroscope
(Carl Zeiss), using 488, 594 and 647 nm excitation wavelengths, for
GFP+, CD13+ and/or NG2+ cells. Two to 3 sections for the striatum
(from +0.98 to −0.02 according to bregma) and 1 to 2 sections for
the SN (from −3,08 to −3.52 according to bregma) were analysed
per animal. For the dorso-lateral and the ventro-medial striatum, 4 pic-
tures of the ipsilateral side were taken at 40× and CD13+, NG2+ and/or
GFP+ pericyte cell somaswere counted. For PDGFRβ+ cells, a 20×mag-
niﬁcation picturewas taken for both ipsilateral striatum regions and the
SN. All cell counts are expressed as percentage of the control. The area
covered by GLUT1+ or CD13+ cells was estimated with the ImageJ soft-
ware (National Health Institute, USA), where 20× magniﬁcation pic-
tures were converted into grayscale pictures, and the threshold toolFig. 2. PDGF-BB induces behavioural recovery. Lesioned animals treated with PDGF-BB showed b
rotation (D) and amphetamine-induced rotation (E) test comparedwith 6-OHDA-lesionedmice
compared to baseline after PDGF-BB treatment. One-way ANOVA with Tukey post-hoc (black a
n = 10; vehicle-treated lesioned group: n = 9; PDGF-BB-treated lesioned group: n = 8. MF
amphetamine.was used to produce a binary image. The total vascular area (GLUT1
staining) was expressed as percentage of the total area. The coverage
of CD13+ pericytes was expressed as percentage of the total GLUT1+
vascular area.
2.10. Protein extraction and western blot
Proteins were precipitated incubating the ﬁrst ﬂowthrough of the
RNeasy mini RNA extraction kit (Quiagen) accordingly to the manufac-
turer instructions with acetone 3:1 v/v for 4 h at −20 °C, before
centrifuging at 15,000 rcf (15 min at 4 °C), prior to collect the protein
pellet.
Protein pellets were resuspended in RIPA buffer (Thermo scientiﬁc)
supplemented with protease inhibitor (Thermo scientiﬁc) and sonicat-
ed 5 × 10 s at 4 °C. Protein concentrations were evaluated with BCA
kit (Pierce), and 5 μg of each sample were incubated in Laemmli bufferehavioural recovery in the corridor (A), stepping (B), cylinder (C), apomorphine-induced
treatedwith vehicle. All 6-OHDA-lesioned animals signiﬁcantly improved their behaviour
sterisks) or paired t-test (blue asterisks), ***p b 0.001, n.s.: non-signiﬁcant. Control group:
B: medial forebrain bundle; i.c.v.: intra-cerebroventricular; APO: apomorphine; AMPH:
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SDS-PAGE and analysed using rabbit anti-NG2 antibody (1:1000,
Millipore), chicken anti-GFP (1:5000, Abcam), rabbit anti-TH (1:1000,
Millipore), and anti-β-actin-HRP antibody (1:10,000, Sigma). Images
were acquired using ChemiDoc MP system (Biorad).
2.11. Statistics
Data were analysed using Graph Pad Prism Software, and are
expressed as mean ± standard deviation. Multiple group comparison
was performed using a one-way ANOVA followed by a Tukey post hoc
test. For comparison of behavioural scores before and after PDGF-BB
treatment, a paired t-test was used. Comparisons were considered sig-
niﬁcant with a p-value b0.05.
3. Results
3.1. PDGF-BB restores behavioural deﬁcits
We ﬁrst investigated whether PDGF-BB restores the behavioural
impairment observed in a unilateral partial 6-OHDA lesion. For this,
behaviour was tested before and 6–8 weeks after the treatment
(Fig. 2).
Before treatment, all selected 6-OHDA-lesioned animals had a signif-
icant behavioural impairment within the cut-off values that wereFig. 3. PDGF-BB partially restores the nigrostriatal DA pathway long-term after treatment. Quantiﬁ
cells in the SN (C) shortly after treatment with vehicle or PDGF-BB. Quantiﬁcation of TH+ ﬁbre
8 weeks after treatment with vehicle or PDGF-BB. One-way ANOVA with Tukey post-hoc, *
lesioned group: n = 3; PDGF-BB-treated 6-OHDA-lesioned group: n = 4. D-F: Control grou
lesioned group: n= 4. SN: substantia nigra.previously described for predicting a partial MFB lesion (Boix et al.,
2015) (Fig. 2A–E). Partially lesioned animals were then randomly divid-
ed to receive either vehicle or PDGF-BB treatment.
Interestingly, PDGF-BB-treated animals displayed behavioural re-
covery and presented behavioural scores similar to controls, but signif-
icantly different from the vehicle-treated 6-OHDA-lesioned group in
both non-drug-induced anddrug-induced behavioural tests. In contrast,
vehicle-treated 6-OHDA-lesioned animals did not show any signiﬁcant
behavioural recovery compared to baseline. These results suggest that
a 2 week i.c.v. administration of PDGF-BB restored the behavioural im-
pairment observed in a unilateral 6-OHDApartial lesionmodel of PD, in-
cluding both non-pharmacological and pharmacological behavioural
tests.
3.2. PDGF-BB partially restores the nigrostriatal DA system
Next we examined whether the observed behavioural recovery was
associated with a restoration of the nigrostriatal DA system (Fig. 3).
Shortly after the end of treatment, the striatal TH+ ﬁbre density was
signiﬁcantly lower in vehicle-treated 6-OHDA-lesioned animals in both
the dorsal and ventral striatum, compared to controls (Fig. 3A and B, re-
spectively). Similarly, the TH+ ﬁbre density was lower in PDGF-BB-
treated 6-OHDA-lesioned animals, both in the dorsal and ventral stria-
tum, but this was not signiﬁcantly different from controls or vehicle-
treated 6-OHDA-lesioned mice. The loss of TH+ ﬁbres was associatedcation of TH+ ﬁbre density in the dorsal (A) and ventral striatum (B) and remaining TH+
density in the dorsal (D) and ventral striatum (E) and remaining TH+ cells in the SN (F)
p b 0.05, **p b 0.01, ***p b 0.001. A-C: Control group: n = 4; Vehicle-treated 6-OHDA-
p: n = 6; Vehicle-treated 6-OHDA-lesioned group: n = 5; PDGF-BB-treated 6-OHDA-
Fig. 4. PDGFRβ+ pericytes are increased in the dorso-lateral striatum in 6-OHDA lesioned mice. Representative pictures of PDGFRβ+ cells in the dorso-lateral lesioned striatum (A)
immediately (upper panel) or 8 weeks (lower panel) after the end of the treatment. Numbers of PDGFRβ+ pericytes are increased in both vehicle- and PDGF-BB-treated 6-OHDA-
lesioned animals (B), immediately (upper panel) or 8 weeks (lower panel) after treatment. No change in PDGFRβ+ pericyte numbers was observed in the ventro-medial striatum (C)
or the SN (D), immediately (upper panel) or 8 weeks (lower panel) after treatment. One-way ANOVA with Tukey post-hoc, *p b 0.05, **p b 0.01. A-D (upper panel): Control group:
n= 4; Vehicle-treated 6-OHDA-lesioned group: n= 3; PDGF-BB-treated 6-OHDA-lesioned group: n= 4. A-D (lower panel): Control group: n= 6; Vehicle-treated 6-OHDA-lesioned
group: n= 5; PDGF-BB-treated 6-OHDA-lesioned group: n= 4. Scale bar = 50 μm.
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compared to controls (Fig. 3C).
Eight weeks after the treatment, vehicle-treated 6-OHDA-lesioned ani-
mals had a striatal TH+ ﬁbre density signiﬁcantly lower than controls both
in the dorsal and ventral striatum (Fig. 3D and E, respectively). 6-OHDA-le-
sioned animals treated with PDGF-BB, in contrast, had a TH+ ﬁbre density
in the ventral striatum that was comparable to controls, and signiﬁcantly
higher than in the vehicle-treated 6-OHDA-lesioned group (Fig. 3E). In
the vehicle-treated lesioned animals, the number of remaining TH+ cellsFig. 5. PDGF-BB normalizes pericyte activation in the dorso-lateral striatum long-term after treatm
striatum (A), immediately (upper panel) or 8 weeks (lower panel) after the end of treatment. I
cells increased in both vehicle- and PDGF-BB-treated 6-OHDA-lesioned groups. Eight weeks a
lesioned animals when using GFP (E), NG2 (F) or both markers (G), coupled with CD13,
ipsilateral striatum (H) showed a similar ﬁnding, with an increase in GFP (I) and NG2 (J) pro
treatment for NG2. One-way ANOVA with Tukey post-hoc, *p b 0.05, **p b 0.01. White r
GFP+CD13+ pericytes. B-D: Control group: n = 4; Vehicle-treated 6-OHDA-lesioned group
Vehicle-treated 6-OHDA-lesioned group: n= 5; PDGF-BB-treated 6-OHDA-lesioned group: n
BB-treated 6-OHDA-lesioned group: n= 4. Scale bar = 50 μm.in the SN was reduced to 64 ± 11% compared to controls (Fig. 3F). This is
associated with a moderate behavioural impairment, whereby the behav-
ioural scores for these partially lesioned animals were within the cut-off
values set for the stepping and amphetamine-induced rotation tests (data
not shown), which conﬁrms our initial selection of partial lesion animals
based on behavioural cut-off values (Boix et al., 2015). PDGF-BB treatment
resulted in a signiﬁcant increase in TH+ cells in the SNpc compared to ve-
hicle-treated 6-OHDA-lesioned mice and a partial restoration of TH+ cells,
when compared to controls at 8 weeks after treatment (Fig. 3F).ent. Representative pictures of GFP+NG2+CD13+ pericytes in the ipsilateral dorso-lateral
mmediately after treatment, GFP+CD13+ (B), NG2+CD13+ (C) or GFP+NG2+CD13+ (D)
fter end of treatment, activated pericytes were still increased in vehicle-treated 6-OHDA-
which was normalized upon PDGF-BB treatment. Western Blot analysis of the whole
tein levels in vehicle-treated 6-OHDA-lesioned mice, which was reversed upon PDGF-BB
ectangles indicate where higher magniﬁcation pictures were taken. Arrows indicate
: n = 3; PDGF-BB-treated 6-OHDA-lesioned group: n = 4. E-G: Control group: n = 6;
= 4. H-J: Control group: n= 4; Vehicle-treated 6-OHDA-lesioned group: n= 4; PDGF-
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the TH+ nigrostriatal DA pathway that is progressive over time.3.3. PDGFRβ+ pericytes are increased in the dorso-lateral striatum in 6-
OHDA-lesioned mice
The main PDGF-BB receptor in vivo is PDGFRβ, which is highly
expressed by pericytes in the brain (Winkler et al., 2010). Therefore,
we next examined whether PDGF-BB treatment is associated with any
changes in PDGFRβ+ pericyte numbers or density.
We found that, shortly after treatment, the number of PDGFRβ+
pericytes was signiﬁcantly increased in the dorso-lateral striatum of 6-
OHDA-lesioned animals, irrespective whether animals were vehicle-
or PDGF-BB-treated (Fig. 4A and B). This increase in PDGFRβ+ pericytes
wasmaintained up to 15 weeks after the 6-OHDA lesion and not affect-
ed by PDGF-BB treatment. PDGFRβ+ pericyte numbers in the ventro-
medial striatum and the SN remained, however, unchanged between
groups (Fig. 4C and D).
These ﬁndings indicate that PDGFRβ+ pericyte numbers increase in
response to the partial 6-OHDA lesion speciﬁcally in the dorso-lateral
striatum.3.4. PDGF-BB modulates pericyte activation in the dorso-lateral striatum
To further characterize PDGF-BB-mediated changes in pericytes in
the partial 6-OHDA lesioned mice, we analysed markers speciﬁc for ac-
tivated pericytes including RGS5 and NG2 (Berger et al., 2005; Ozerdem
et al., 2001).
We ﬁrst used immunoﬂuorescence staining for GFP (RGS5) and
NG2, in combination with the pericyte marker CD13 (Fig. 5A). Shortly
after end of treatment, GFP+CD13+ cells were increased by 1.5-fold in
all 6-OHDA-lesionedmicewhen compared to controls (Fig. 5B). Similar-
ly, NG2+CD13+ pericytes were increased by 2.5-fold in both 6-OHDA-
lesioned groups compared to controls, which was signiﬁcant for the ve-
hicle-treated, but not for the PDGF-BB-treated group (p= 0.054) (Fig.
5C). The same phenomenon was observed for GFP+NG2+CD13+ triple
labelled cells showing a 3 and 2.5 fold increase, respectively, in the vehi-
cle- or PDGF-BB-treated 6-OHDA-lesioned groups (Fig. 5D).
At 8 weeks after the end of treatment, the number of GFP+CD13+
pericytes was still signiﬁcantly higher in vehicle-treated 6-OHDA-le-
sioned mice versus controls (Fig. 5E). Interestingly, PDGF-BB treatment
in 6-OHDA-lesioned mice led to a decrease in the number of
GFP+CD13+ pericytes, even though this did not reach statistical signif-
icance. However, PDGF-BB treatment normalized the number of
NG2+CD13+ pericytes 8 weeks post-treatment to levels similar to the
control group, whereas NG2-expressing CD13+ pericytes were still 3-
fold higher in the vehicle-treated 6-OHDA-lesioned group (Fig. 5F).
GFP+NG2+CD13+ pericytes were 5-fold increased in the vehicle-treat-
ed 6-OHDA-lesioned group, but less in the PDGF-BB-treated 6-OHDA-
lesioned group, even though this difference was not signiﬁcant (Fig.
5G).
Secondly, we quantiﬁed the protein expression of GFP and NG2
using western blot in the ipsilateral striatum 8 weeks after the end of
the treatment (Fig. 5H), conﬁrming an increase of 2.5 and 3.5 fold for
GFP and NG2 protein expression, respectively, in the vehicle-treated
6-OHDA-lesioned group (Fig. 5I and J). Upon PDGF-BB treatment, NG2
protein was signiﬁcantly decreased to levels similar to the control
group, consistent with the immunohistochemical analysis.
In the ventro-medial striatum (Supplementary Fig. 1), pericyte acti-
vation was also increased in the 6-OHDA-lesioned groups, irrespective
of treatment. However, 8 weeks after treatment, there were no signiﬁ-
cant differences between groups. Similarly, there were no signiﬁcant
differences in the numbers of activated pericytes between groups in
the SN (data not shown).Taken together, these data indicates that striatal pericytes are acti-
vated after a partial 6-OHDA lesion, which can be reversed by PDGF-
BB 8 weeks after the end of the treatment.
3.5. PDGF-BB normalizes pericyte coverage, but has no effect on the vascu-
lar density in the dorso-lateral striatum
We next investigated whether the pericyte coverage on blood ves-
sels is affected by a partial 6-OHDA lesion or PDGF-BB treatment (Fig. 6).
Shortly after the end of the treatment, CD13+ cell numbers, the
CD13+ pericyte coverage of blood vessel and the total vascular density
in the dorso-lateral striatumwas similar in all groups (Fig. 6A-D). How-
ever, 8 weeks after treatment, the CD13+ pericyte coverage had in-
creased signiﬁcantly in the vehicle-treated 6-OHDA-lesioned group
compared to controls, while CD13+ cell numbers and the vascular den-
sity were unchanged (Fig. 6E-H). Eight weeks after treatment, PDGF-BB
had normalized the covered area of CD13+ cells to values comparable to
controls.
These results indicate that CD13 expression rather than CD13+ cell
numbers increases signiﬁcantly in the dorso-lateral striatum, long-
term after a partial 6-OHDA lesion, which is normalized upon PDGF-
BB treatment.
4. Discussion
Here we demonstrate that a 2-week i.c.v. treatment with PDGF-BB
leads to a robust behavioural recovery in a partial 6-OHDA lesion
mousemodel of PD twomonths after end of treatment by using several
pharmacological and non-pharmacological tests. The behavioural
changes are associatedwith a partial restoration of the nigrostriatal sys-
tem. Furthermore, we show for the ﬁrst time that a partial 6-OHDA le-
sion is paralleled by an increase in pericyte numbers in the striatum,
and, in particular, an activation of pericytes. Interestingly, we ﬁnd that
this activated state of pericytes is partially reversed upon PDGF-BB
treatment. Thus, PDGF-BB may exert its restorative effect via modula-
tion of pericytes.
Herewe extend previous ﬁndings (Zachrisson et al., 2011) and show
behavioural recovery in response to PDGF-BB i.c.v. treatment not only in
the amphetamine-induced rotation test (Zachrisson et al., 2011), but
also for the apomorphine-induced rotation test, as well as for three
non drug-induced behavioural tests: the cylinder, stepping and corridor
test. This demonstrates a clear effect of PDGF-BB that lasts at least
2 months after treatment, which is of relevance for the design of future
clinical studies, as it indicates that PDGF-BB may not have to be contin-
uously infused, but can rather be administered at intervals.
PDGF-BB-induced behavioural recovery was associated with a sig-
niﬁcant increase in striatal TH+ ﬁbre density and a partial restoration
of TH+ cell numbers in the SN, 8 weeks after the end of treatment,
conﬁrming previous ﬁndings in other rodent PD models (Zachrisson et
al., 2011) and in non-human primates (Paul et al., 2013). This partial
restoration was sufﬁcient to elicit a complete behavioural recovery
after PDGF-BB treatment. The remaining TH+ cell loss in PDGF-BB-treat-
ed lesioned animals was so mild that the behavioural performance was
comparable to controls. In addition, the increase in TH+ ﬁbre density in
PDGF-BB-treated lesioned animals may also have contributed to the be-
havioural recovery.
Recently, i.c.v. delivery of PDGF-BB has been investigated in a phase-
1 clinical trial in PD patients and a dose-dependent increase in dopa-
mine transporter binding in the putamen was seen, suggesting a possi-
ble regenerative effect on striatal DA ﬁbres also in patients (Paul et al.,
2015), consistent with our ﬁndings.
The increase in TH+ cell numbers in the SN is most likely due to an
upregulation of TH in the remainingDA cells rather than due to prolifer-
ation of TH+ cells as neurogenesis in the SN has not been observed
(Frielingsdorf et al., 2004). Tyrosine hydroxylase is the rate-limiting en-
zyme for dopamine synthesis and a marker for DA neurons. It has been
Fig. 6. PDGF-BB reduces CD13+ pericyte coverage but did not affect GLUT1+ vascular density in the dorso-lateral lesioned striatum. Representative pictures of CD13 and GLUT1 staining in the
dorso-lateral striatum ipsilateral to the lesion, shortly after end of treatment (A). Nodifferencewas observedbetween groups for CD13+ cell numbers (B), the CD13+pericyte coverage (C)
and the vascular density (GLUT1+) (D). Representative pictures of CD13andGLUT1 staining in thedorso-lateral striatum, 8weeks after end of treatment (E).While theCD13+ cell number
remained unchanged in all groups (F), CD13+ coverage was increased in the vehicle-treated 6-OHDA-lesioned group, but not with PDGF-BB treatment (G). There was no difference in
vascular density between groups. One-way ANOVA with Tukey post-hoc, *p b 0.05, **p b 0.01. B-D: Control group: n= 4; Vehicle-treated 6-OHDA-lesioned group: n= 3; PDGF-BB-
treated 6-OHDA-lesioned group: n= 4. F–H: Control group: n= 6; Vehicle-treated 6-OHDA-lesioned group: n= 5; PDGF-BB-treated 6-OHDA-lesioned group: n= 4. Scale bar: 100 μm.
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apoptosis (Bowenkamp et al., 1996; Kordower et al., 2013), indicating
that the DA phenotype can be rescued using neurorestorative agents.
Thus, PDGF-BB either directly or indirectly promotes dysfunctional DA
cells to regain their TH expression and DA neuronal phenotype, and
their functionality. This implicates that this treatmentmay bemost ben-
eﬁcial if administered during early or mid stage of the disease, before
the majority of cells and ﬁbres are already lost.
The cerebralmicrovasculature is widely known to undergo structur-
al and functional alterations that may play a role in the pathogenesis
and pathophysiology of neurodegenerative disorder like Alzheimer's
disease and PD (Farkas et al., 2000; Sagare et al., 2013). Indeed, both
in animal models of PD and in post mortem brain sections of PD pa-
tients, several vascular alterations have been described (Barcia et al.,
2005; Carvey et al., 2005; Chen et al., 2008; Desai Bradaric et al., 2012;
Janelidze et al., 2015; Kortekaas et al., 2005; Wada et al., 2006; Yang et
al., 2015).
Pericytes are a key component of the neurovascular unit, but pheno-
typic and morphological changes of pericytes have not been investigat-
ed in PD. We describe for the ﬁrst time an increase in PDGFRβ+
pericytes in the dorso-lateral lesioned striatum in a PD mouse model
that persists over the time period observed. PDGFRβ is the main recep-
tor for PDGF-BB in vivo and is expressed only by pericytes in the brain
(Winkler et al., 2010). This increase in PDGFRβ+ pericytes may indicate
a response to the TH+ ﬁbre loss or dopamine depletion that ismost pro-
nounced in the dorso-lateral striatum.
Activated pericytes express several typical markers such as RGS5
(Berger et al., 2005) and NG2 (Ozerdem et al., 2001), proteins related
to vessel remodeling. Interestingly, we ﬁnd a clear activation of
pericytes in the dorso-lateral striatum after the lesion. Pericyte activa-
tion was partially reversed upon PDGF-BB treatment, but persisted in
vehicle-treated 6-OHDA-lesioned mice. This effect could be due to a di-
rectmechanism of PDGF-BB on pericytes that leads to vascular stabiliza-
tion, and thus may decrease the number of activated pericytes. Indeed,
PDGF-BB has been shown to negatively regulate RGS5 expression (Cho
et al., 2003; Gunaje et al., 2011) and promote pericyte recruitment to
stabilize the newly formed blood vessels (Clapp et al., 2009). Therefore,
PDGF-BB treatment couldmediate a shift between pericyte phenotypes,
from an activated to a more resting state. Another more indirect mech-
anism is also conceivable. It has been shown that dopamine prevents
vascular abnormalities in tumours (Chakroborty et al., 2011). The dopa-
mine loss observed in the striatum of 6-OHDA-lesioned animals might
therefore lead to an aberrant angiogenic vascular response and activa-
tion of pericytes. Restoration of TH+ ﬁbres and cells would lead to nor-
malisation of the striatal dopamine level, which in turn would result in
normalisation of an overshooting pericyte activation. This would be in
agreement with the delayed recovery of TH+ ﬁbres and cells after end
of treatment.
Consistently, we also observed a signiﬁcant increase in CD13 expres-
sion in 6-OHDA-lesioned animals that was reversed by PDGF-BB. CD13
levels are known to increase upon angiogenesis and inﬂammation (Di
Matteo et al., 2011; Huschak et al., 2003). PDGF-BB may reduce the in-
ﬂammation in the striatum and CD13 expression. Alternatively,
pericytes are known to acquire a different morphology when activated,
with a more bulging soma and more stretched processes (Dore-Duffy
and Cleary, 2011). This would explain the increase in the CD13+ area
coverage in 6-OHDA-lesioned mice and the PDGF-BB-induced normal-
isation solely long after the treatment, as the PDGF-BB effect on pericyte
activation is observed only at the long-term time point.
In our study, the vascular density was not affected by the lesion or
the PDGF-BB treatment. This may be explained by the fact that our
PD model is a partial lesion model and that the nature and extent
of vascular changes in PD have been variable (Yang et al., 2015).
Also, it remains to be investigated in more detail whether the
PDGF-BB-mediated pericyte modulation may differ depending on
age or stage of disease.5. Conclusion
In conclusion,we demonstrated that i.c.v. PDGF-BB infusion promot-
ed robust behavioural recovery persisting for at least 2 months in 5 dif-
ferent behavioural tests, whichwas associatedwith a partial restoration
of the nigrostriatal pathway. Pericytes are activated in PD in response to
the lesion, and this activation is reversed by PDGF-BB treatment. Our
data suggest that brain pericytes may play a role in the pathogenesis
of PD and could constitute a target for the PDGF-BB-induced
neurorestorativemechanism in PD. Future studies will further elucidate
the pathophysiological mechanism connecting PD and vascular changes
and in particular, the role of pericyte function and dysfunction in PD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.06.002.
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